Bayer to file long-acting Factor VIII as data ease infusion burden
This article was originally published in Scrip
Bayer's long-acting recombinant Factor VIII compound BAY94-9027 has met primary efficacy and safety endpoints in a Phase III trial in patients with hemophila A. The data from the PROTECT VIII trial also showed that BAY94-9027 extended the interval for infusion needed by seven days.
You may also be interested in...
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.
Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.